Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07046806 · ClinicalTrials.gov registry record · Phase 1
Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients
A Phase 1 study of Hereditary Angioedema (HAE) and Angioedema, sponsored by Institute for Asthma and Allergy.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07046806: Recruiting Phase 1 study of Hereditary Angioedema (HAE) and Angioedema, sponsored by Institute for Asthma and Allergy.
NCT07046806 is a Phase 1 study of Hereditary Angioedema (HAE) and Angioedema that is actively recruiting participants, run by Institute for Asthma and Allergy. The registered enrollment target is 10 participants, below the 66-participant average among 7 other Hereditary Angioedema (HAE) trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07046806, a Phase 1 study of Hereditary Angioedema (HAE) and Angioedema, is actively recruiting participants, sponsored by Institute for Asthma and Allergy.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the efficacy of prophylactic treatment with deucrictibant extended release (XR) tablet versus placebo in preventing angioedema attacks, and to also assess the efficacy of deucrictibant soft capsules as on-demand treatment versus placebo in achieving angioedema symptom relief during acute attacks.
Primary Outcome
Part-1: Time-normalized number of Investigator-confirmed moderate or severe angioedema attacks during the Treatment Period. Time-normalized number of Investigator-confirmed angioedema attacks treated with on-demand medication during the Treatment Period.
Conditions Studied
Interventions
- DRUG Deucrictibant XR tablet
- DRUG Placebo comparator to XR tablet
- DRUG Deucrictibant 20 mg capsule
- DRUG Placebo comparator to 20 mg capsule
Study Locations (1)
Maryland
- Institute For Asthma & Allergy - Wheaton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 1 |
What NCT07046806 shows while recruiting
NCT07046806 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 66-participant average among 7 other Hereditary Angioedema (HAE) trials with a reported enrollment target (85% lower).
The record links to 4 conditions, with Hereditary Angioedema (HAE) appearing as the primary indexed condition, and to 4 interventions - of which Deucrictibant XR tablet is the first listed.
NCT07046806 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT07046806 about?
NCT07046806 is a clinical study titled "Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients". To assess the efficacy of prophylactic treatment with deucrictibant extended release (XR) tablet versus placebo in preventing angioedema attacks, and to also assess the efficacy of deucrictibant soft capsules as on-demand treatment versus placebo in achieving angioedema symptom relief during acute a...
What is the current status of trial NCT07046806?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-03-10. Estimated completion is 2026-04-01.
What conditions does trial NCT07046806 study?
This clinical trial studies the following conditions: Hereditary Angioedema (HAE), Angioedema, Bradykinin-mediated Angioedema, C1 Inhibitor Deficiency.
What interventions are being tested in trial NCT07046806?
The interventions under investigation include: Deucrictibant XR tablet (DRUG), Placebo comparator to XR tablet (DRUG), Deucrictibant 20 mg capsule (DRUG), Placebo comparator to 20 mg capsule (DRUG).
Who is sponsoring clinical trial NCT07046806?
This trial is sponsored by Institute for Asthma and Allergy, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07046806 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Angioedema (HAE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Navenibart in Participants With Hereditary Angioedema
RECRUITING · Phase 3
-
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
RECRUITING · Phase 3
-
Donidalorsen Treatment in Children With Hereditary Angioedema
RECRUITING · Phase 3
-
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 2 in Adult Subjects With Hereditary Angioedema
ACTIVE NOT RECRUITING · Phase 2
-
CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI